Search results
Showing 1606 to 1620 of 9082 results
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.
Show all sections
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA1021)
Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults.
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis (TA1155)
Evidence-based recommendations on rozanolixizumab (Rystiggo) for treating antibody-positive generalised myasthenia gravis in adults.
Evidence-based recommendations on tisotumab vedotin (Tivdak) for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment in adults.
Show all sections
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating acute uncomplicated influenza in people aged 12 and over. This is because Roche did not provide an evidence submission.
Show all sections
Sections for TA732
Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.
Evidence-based recommendations on mepolizumab (Nucala) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.
Evidence-based recommendations on serplulimab (Hetronifly) with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer in adults.
Show all sections
NICE is unable to make a recommendation on imlunestrant (Inluriyo) for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1168